Request an Appointment

Book an appointment with Dr. Jeffrey Matous

Presbyterian/St. Luke's Medical Center

Physicians participating in the referral service program have chosen to participate, are in good standing at our hospitals and have not paid a fee to participate. They are credentialed to perform the service you have requested and are accepting new patients. They do not have a financial interest in another hospital or facility in this area and are not employed by or have an ownership interest in a competitive health care system. To ensure patients have a reasonable number of physician choices, the program includes physicians who may not have privileges at our hospital but have an office location in our hospital's primary service area or have been granted access to our hospital's clinical information systems. Physicians who are employed or engaged by an HCA affiliated physician practice or offering online appointment scheduling are referred first with others referred on a randomized basis to match your individual needs with consideration for the preferences you have expressed.

Jeffrey Victor Matous MD

Hematology•Denver, CO

Hematologic Oncology

Member Colorado Blood Cancer Institute Sarah Cannon Research Institute Clinical Professor of Medicine, University Colorado

Request appointment

1721 E 19th Ave#300Denver, CO 80218
Book by Phone+1(720) 823-4702

Overview of Dr. Matous

Jeffrey Matous, MD, is a hematologist who focuses on the treatment of plasma cell diseases, especially clinical care and research for patients who have multiple myeloma, Waldenström Macroglobulinemia and amyloidosis. Dr. Matous is passionate about educating his patients about these diseases and is experienced in the field of blood and marrow transplantation as a treatment therapy.

Dr. Matous was born in Sarnia, Ontario, Canada and raised in Seattle, WA; he received his medical degree with honors from the University of Washington. Dr. Matous then completed his internal medicine residency and chief residency at the University of Colorado Health Sciences Center. His fellowship training in hematology and bone marrow transplantation was completed at the University of Washington and the Fred Hutchinson Cancer Research Center. He then returned to Denver to practice and has been with the CBCI team since 2010. In addition to his work with our patients and team, Dr. Matous is also a clinical professor of medicine at the University of Colorado, a member of the Sarah Cannon Research Institute Myeloma Executive Committee and serves on the International Waldenström Macroglobulinemia Working Group.

He has been recognized as an outstanding clinical teacher of the medicine house staff. Further, Dr. Matous is the lead investigator in clinical trials in the areas of Waldenstrom’s Macroglobulinemia, multiple myeloma, and amyloidosis, and has been recognized by his peers as a Top Doctor regularly for more than two decades.

Dr. Matous is married with three adult children. Outside of work he enjoys cycling, languages, and our nation’s pastime.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1994
University of ColoradoResidency, Internal Medicine, 1985 - 1989
University of Washington School of MedicineClass of 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CO State Medical License 1988 - 2027
MT State Medical License 2004 - 2027
NE State Medical License 2003 - 2022
American Board of Internal Medicine Internal Medicine

Clinical Trials

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
UNKNOWN
PHASE2
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
UNKNOWN
PHASE2
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
UNKNOWN
PHASE2

Publications & Presentations

PubMed

Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.
Peter A Forsberg, Jacqueline A Turner, Marita Meyer, Diana Abbott, Sara Nicholson
Blood Advances. 2026-05-26
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics an...
Natalia A Quijano Cardé, Jin Niu, Yue Guo, Jia Zhou, Xiao Qiu
Targeted Oncology. 2026-05-01
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Omar Nadeem, Michelle P Aranha, Robert A Redd, Michael Koontz, Jeffrey V Matous
Nature Communications. 2026-04-08

Journal Articles

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Jeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine

Abstracts/Posters

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
Jeffrey V. Matous, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem PPO
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment